The pregnancy hormone relaxin (RLX) is a powerful cardiostimulatory peptide. Despite its well-characterized effects on the heart, the intracellular mechanisms responsible for RLX's positive inotropic effects are unknown. Cardiac myofilaments are the central contractile elements of the heart, and changes in the phosphorylation status of myofilament proteins are known to mediate changes in function. The first objective of this study was to determine whether RLX stimulates myofilament activation and alters the phosphorylation of one or more myofilament proteins. RLX works through a variety of intracellular signaling cascades in different tissue types. Protein kinases A (PKA) and C (PKC) are two common molecules implicated in RLX signaling and are known to affect myofilament function. Thus the second objective of this study was to determine whether RLX mediates its myocardial effects through PKA or PKC activation. Murine myocardium was treated with recombinant H2-RLX, and cardiac myofilaments were isolated. RLX increased cardiac myofilament force development at physiological levels of intracellular Ca 2ϩ without altering myofilament ATP consumption. Myosin binding protein C, troponin T, and troponin I phosphorylation levels were increased with RLX treatment. Immunoblot analysis revealed an increase in myofilament-associated PKC-␦, decreases in PKC-␣ and -␤ II, but no effect on PKC-ε. Inhibition of PKC with chelerythrine chloride or PKC-␦ with rottlerin prevented the RLX-dependent changes in myofilament function and protein phosphorylation. PKA antagonism with H-89 had no effect on the myofilament effects of RLX. This study is the first to show that RLX-dependent changes in myofilament-associated PKC alters myofilament activation in a manner consistent with its cardiostimulatory effects.
in the face of increasing demands produced by the developing fetus (27) . Some studies have reported that circulating levels of relaxin are elevated in heart failure patients (5, 6) , while others have not been able to replicate these findings (13) . A significant obstacle in understanding the physiological and pathophysiological roles of relaxin in the cardiovascular system is the general lack of information about its fundamental mechanisms of action.
Cardiac myofilaments are the contractile apparatus of the heart, and their interaction with calcium forms the basis for myocardial contraction. Modifications of these proteins are known to influence heart function under both physiological and disease conditions (3, 12, 29) . It is known that relaxin increases myocardial contractility, but the intracellular mechanisms of this phenomenon are unknown. The first aim of this study was to determine whether relaxin affects cardiac myofilament function in a manner that is consistent with its positive inotropic effects on the heart.
Relaxin works through a variety of intracellular second messengers, including protein kinases A (PKA) (16, 20) and C (PKC) (11, 17) . The molecular signals activated by relaxin vary, depending on the cell type. Whether relaxin activates PKA or PKC to modify cardiac myofilaments has never been investigated. The second aim of our study was to determine whether relaxin activated one or both of these intracellular kinases in myocardium.
Together, the aims of this study represent the first known attempt to characterize the effects of relaxin on cardiac myofilaments, and to identify the intracellular signals activated by this hormone in the myocardium. Such information is crucial in the identification of relaxin as a beneficial or detrimental agent of the heart.
METHODS
Agonist and antagonist and treatment. Hearts were excised from C57/Bl6 female mice (4 to 6 mo old), euthanized with carbon dioxide, and rinsed in ice-cold saline. The heart was cut into strips and placed in oxygenated (95% O 2-5% CO2) Krebs-Henseleit solution containing agonists/antagonists. Ventricular myocardium was treated with 30 nmol recombinent H-2 relaxin (generous gift of E. Unemori, formerly of Connectics, Palo Alto, CA) for 10 min at room temperature. H-2 relaxin is the predominant circulating isoform in human plasma and is the equivalent of the major circulating mouse isoform. The concentration of relaxin has been shown to exert maximal cardiac effects at 7-10 min (10, 31) and to provide protection against ischemiareperfusion injury (15) . Moreover, this concentration falls within the physiological range of serum relaxin observed in pregnant rodents (27) .
To assess the involvement of various intracellular messengers, ventricular muscle was exposed to antagonists for 5 min before relaxin treatment. Chelerythrine chloride (2 M) and bisindolmaleimide (100 nM) have been shown to effectively inhibit PKC activation (22) . Rottlerin (5 M) is a potent inhibitor of PKC-␦ (7). H-89 (100 nM) was used to block PKA activation (22) .
Isolation of myofilaments.
Cardiac muscle was treated with agonists/antagonists and then homogenized in ice-cold intracellular buffer. Myofilaments were isolated from ventricles, as described previously (22, 23) . Briefly, the homogenate was centrifuged at 12,000 g for 15 min at 4°C. Pellets were dissolved in skinning buffer and left on ice for 45 min before centrifugation was repeated. Resulting pellets were washed three times in ice-cold intracellular buffer, and purified myofilaments were stored on ice for up to 2 h or frozen for gel electrophoresis.
Actomyosin Mg 2ϩ -ATPase. Actomyosin Mg 2ϩ -ATPase activity was measured using spectrophotometry. Purified myofilaments (50 g) were incubated in activating solutions containing varying levels of free calcium created using combinations of activating and relaxing buffers. Free calcium was calculated using the program from Patton et al. (19) . Myofilaments were incubated in activating buffers for 5 min at 32°C, and reactions were quenched with 10% trichloroacetic acid. The amount of inorganic phosphate produced was measured by adding an equal volume of 0.5% FeSO 4 and 0.5% ammonium molybdate in 0.5 M H2SO4, and reading the absorbance at 630 nm.
Isometric force. Hearts were excised from mice and rinsed free of blood in ice-cold saline (0.9% NaCl), and left ventricular papillary fibers were quickly dissected free. After incubation with agonists/ antagonists, papillary muscles were placed in ice-cold relaxing buffer and cut into fiber bundles. Triton X-100 (1% vol/vol final concentration) was added to chemically permeabilize the preparations overnight at 4°C.
Permeabilized papillary fibers were attached to a force transducer at one end and a linear motor at the other (Scientific Instruments, Heidelberg, Germany). Sarcomere length was measured by laser diffraction and adjusted to 2.25 m in relaxing buffer. Fiber bundles were equilibrated for 5 min in relaxing buffer before being exposed to activating solutions containing increasing amounts of free calcium. Sigmoidal calcium-tension relations were fit by a nonlinear procedure to a modified Hill equation:
where T is isometric tension, max is the maximum value at saturating Ca 2ϩ concentration ([Ca 2ϩ ]), EC50 is the [Ca 2ϩ ] at which 50% of maximum isometric tension is reached, and H is the slope of the relationship (Hill coefficient).
Protein phosphorylation. Myofilament proteins (40 g) were separated on 12.5% sodium-dodecyl sulfate-polyacrylamide gels. Gels were fixed in 50% methanol-10% acetic acid at room temperature overnight, and phosphorylated proteins were stained with Pro-Q Diamond (Molecular Probes, Eugene, OR), according to the manufacturer's instructions. Imaging was done using a Typhoon gel scanner (GE Healthcare, Baie, Quebec), and analysis was done using Image J software (NIH, Bethesda, MD). Protein loading was assessed by Coomassie staining of gels after imaging.
PKC immunoblotting. PKC immunoblotting was performed using a modified protocol from Pyle et al. (22, 24) . Myofilament proteins (75 g) were resolved by sodium-dodecyl sulfate-polyacrylamide gel electrophoresis using 10% separating gel. Proteins were transferred to nitrocellulose membranes and probed with antibodies for PKC-␣, PKC-␤ II, PKC-␦, and PKC-ε (BD Biosciences, Mississauga, Ontario, Fig. 1 . Acute relaxin treatment of mouse myocardium alters force-and actomyosin Mg-ATPase-Ca 2ϩ relationships. Mouse myocardium was treated with recombinant H-2 relaxin, and cardiac myofilaments were isolated posttreatment. A: isometric force at levels of Ca 2ϩ Ͼ 0.2 M was significantly enhanced by relaxin (P Ͻ 0.05), as evidenced by the leftward shift in the force-Ca 2ϩ curve. Maximum isometric force and the steepness of the curve were unaltered by relaxin treatment. A total of 4 hearts and 8 fiber bundles were used for each group. B: actomyosin Mg-ATPase activity at levels of Ca 2ϩ Ͼ 0.7 M was significantly decreased by relaxin (P Ͻ 0.05). By contrast, relaxin had no effect on myofilament Ca 2ϩ sensitivity or the slope of the curve. Values are means Ϯ SE; N ϭ 14 hearts for each group. Canada, and Upstate, Mississauga, Ontario, Canada). Phospho-T505 PKC-␦ antibody (New England Biolaboratories, Ipswich, MA) was used to asses PKC-␦ activation. Protein loading was assessed by probing with an anti-actin antibody (Millipore, Etobicoke, Ontario, Canada). Secondary antibodies were conjugated to horseradish peroxidase. Primary antibodies were used at 1:1,000 dilution, except for anti-actin, which was 1:25,000. Secondary antibodies were used at 1:5,000 dilution. PKC bands were detected using Western Lightning (PerkinElmer Life and Analytical Sciences, Woodbridge, Ontario, Canada), and analysis of band density was done using Image J software. All bands were normalized to their respective controls and are expressed as a percent change in band density.
Solutions. Krebs-Henseleit buffer contained 118.5 mM NaCl, 5 mM KCl, 1.2 mM MgSO 4, 2 mM NaH2PO4, 26.6 mM NaHCO3, 10 mM glucose, and 0.2 mM CaCl2. Intracellular buffer contained 60 mM KCl, 30 mM imidazole (pH 7.0), 2 mM MgCl2, 0.01 mM leupeptin, 0.1 mM PMSF, and 0.2 mM benzamidine. Skinning buffer with 1% Triton contained 10 mM EGTA (pH 7.0), 8.2 mM MgCl 2, 14.4 mM KCl, 60 mM imidazole (pH 7.0), 5.5 mM Na2ATP, 12 mM creatine phosphate, 10 U/ml creatine phosphokinase, 0.01 mM leupeptin, 0.1 Fig. 2 . Relaxin increases myofilament protein phosphorylation in murine myocardium. A: cardiac myofilaments were isolated post-relaxin treatment, and proteins were separated by SDS-PAGE. Relaxin increased total phosphorylation levels of myosin binding protein C (MyBP-C), troponin T (TnT), and troponin I (TnI). B: histogram illustrating mean Ϯ SE changes in myofilament protein phosphorylation. N ϭ 8 hearts for each group. *P Ͻ 0.05 vs. control. Fig. 3 . PKC antagonism blocks relaxin-dependent alterations in cardiac myofilament function. Before and during relaxin treatment of myocardium, inhibitors of PKA or PKC were included. A: relaxin significantly increased isometric force at levels of Ca 2ϩ Ͼ 0.2 M (P Ͻ 0.05 vs. control). Inhibition of PKA with H-89 had no effect on relaxin-dependent changes in isometric force, while PKC inhibition with chelerythrine chloride completely abolished the relaxindependent increase in myofilament Ca 2ϩ sensitivity. Neither chelerythrine chloride nor H-89 affected isometric force development (data not shown). Values are means Ϯ SE; N ϭ 4 hearts and 8 fiber bundles in each treatment group. B: relaxin significantly decreased actomyosin Mg-ATPase activity at levels of Ca 2ϩ Ͼ 0.7 M (P Ͻ 0.05 vs. control). The reduction in actomyosin Mg-ATPase activity was blocked with PKC inhibition by chelerythrine chloride, but not the PKA antagonist H-89. H-89 and chelerythrine chloride by themselves did not affect actomyosin Mg-ATPase activity (data not shown). Values are means Ϯ SE; N ϭ 14 hearts for control and relaxin groups, and N ϭ 7 hearts for relaxin ϩ chelerythrine and relaxin ϩ H-89. 
RESULTS

Relaxin modifies cardiac myofilament activation.
Relaxin is a known cardiostimulatory compound, with inotropic effects that are more potent than endothelin, angiotensin II, and isoprenaline (10) . To determine whether the myocardial effects of relaxin may be mediated through changes in cardiac myofilaments, we examined myofilament function of murine hearts after relaxin treatment. Maximum actomyosin Mg-ATPase activity was reduced following relaxin treatment, whereas EC 50 and the Hill coefficient were unaffected (Fig. 1, Table 1 ). By contrast, relaxin induced a leftward shift in the isometric tension-Ca 2ϩ relationship, demonstrating an increase in myofilament Ca 2ϩ sensitivity, without affecting maximum tension development or the Hill coefficient. Together, these results support our hypothesis that relaxin targets cardiac myofilaments in a manner that is consistent with its previously reported positive inotropic effects.
Cardiac myofilaments exhibit increased phosphorylation following relaxin treatment. Rapid regulation of cardiac myofilaments can be mediated through changes in the phosphorylation status of several myofilament proteins. We sought to determine whether relaxin-dependent changes in myofilament function were associated with alterations in the phosphorylation of cardiac myofilament components. Troponin I, troponin T, and myosin binding protein C demonstrated significant increases in phosphorylation levels following relaxin treatment (Fig. 2) . These results represent the first data showing alterations in cardiac myofilament protein phosphorylation with relaxin treatment.
PKC inhibition blocks myofilament regulation by relaxin. Relaxin transduces its intracellular effects through cell-dependent pathways, including PKC (11, 17) and PKA (16, 20) . To ascertain if relaxin mediates its effects on cardiac myofilaments through PKC or PKA, we treated myocardium with kinasespecific inhibitors before relaxin exposure. The PKC inhibitors chelerythrine chloride and bisindolmaleimide both blocked relaxin-dependent effects on cardiac myofilament function (Fig. 3, Table 2 ). The PKA inhibitor H-89 was ineffective in altering relaxin-dependent changes in actomyosin Mg-ATPase activity or myofilament force. Moreover, PKC inhibition blocked the relaxin-dependent changes in myofilament protein phosphorylation, whereas PKA antagonism had no effect (Fig. 4) . These results indicate that relaxin mediates its myofilament alterations through a PKC-dependent pathway in the mouse heart.
Relaxin alters cardiac myofilament-associated PKC. PKC is a family of serine-threonine kinases, consisting of several isoforms. To determine which PKC isoforms associated with cardiac myofilaments are affected by relaxin treatment of ventricular myocardium, we examined myofilament-associated PKC by immunoblot analysis. No changes in myofilament-associated PKC-ε were observed, but a significant increase in PKC-␦ occurred following relaxin treatment (Fig. 5) . Relaxin also significantly decreased myofilament levels of PKC-␣ and -␤ II . These data indicate that relaxin alters myofilament-associated PKC in murine myocardium.
PKC-␦ mediates relaxin-dependent changes in cardiac myofilaments.
Protein levels of myofilament-associated PKC-␦ increased following relaxin treatment of ventricular myocardium. To determine whether PKC-␦ mediated any or all of the effects of relaxin on cardiac myofilaments, we examined PKC-␦ phosphorylation and how inhibition of PKC-␦ affected relaxin-dependent regulation of cardiac myofilaments. Inhibition of PKC-␦ with rottlerin antagonized the effects of relaxin on both actomyosin Mg-ATPase activity and myofilament protein phosphorylation (Fig. 6) . Immunoblot analysis probing for PKC-␦ phosphorylation at T505 was used to examine PKC-␦ activation. Interestingly, there were no significant changes in PKC-␦ phosphorylation at T505. Together, these data indicate that relaxin mediates control over cardiac myofilaments through a PKC-␦-dependent pathway that does not require the phosphorylation of PKC-␦ at T505.
DISCUSSION
The pregnancy hormone relaxin is a potent cardiotrophic compound whose mechanisms of action in the heart are largely unknown. We present here the first data showing that relaxin acutely modifies cardiac myofilaments through a PKC-dependent pathway to increase myofilament Ca 2ϩ sensitivity of force. These results are consistent with a model of relaxindependent regulation of myocardial function in which en- hanced myofilament activation contributes to the positive ionotropic effects of this hormone. Relaxin works through a variety of intracellular signaling pathways, depending on the cell type. Our finding that relaxin mediates myocardial changes through a PKC-dependent cascade is consistent with work by other groups using noncardiac cells (11, 17) . However, we failed to detect any PKA-dependent alterations in myofilament function with relaxin treatment, which is in disagreement with a previous study showing that relaxin activated PKA in atrial myocytes (20) . The discrepancy between our work and that of Piedras-Renteria et al. (20) could be attributed to a number of important differences between the studies. First, intracellular signaling cascades can exhibit activity profiles that differ across intracellular compartments. Thus it is possible that relaxin activates the PKA pathway near the membrane-bound ionic channels investigated by PiedrasRenteria et al. (20) , whereas the myofilament compartment is not exposed to alterations in PKA activity. Moreover it has been shown that relaxin-dependent increases in cAMP can occur in a biphasic pattern with a rapid (i.e., Ͻ5 min) spike followed by a rapid decline, while others have found that the increase in cAMP occurs over a prolonged period, peaking at 30 min posttreatment (9). Our relaxin treatment protocol was designed to examine the time period corresponding to the Fig. 4 . Blockade of PKC activation prevents increased myofilament protein phosphorylation by relaxin. Myocardium was treated with relaxin and inhibitors of PKC or PKA. A: cardiac myofilaments were isolated and separated using SDS-PAGE. Left: relaxin increased phosphorylation of MyBP-C, TnT, and TnI. PKC inhibition with chelerythrine chloride abolished the relaxin-dependent increase in MyBP-C, TnT, and TnI. PKA inhibition with H-89 had no effect on the relaxin-dependent increases in myofilament protein phosphorylation. Neither chelerythrine chloride nor H-89 had any effect on myofilament protein phosphorylation. Right: the corresponding Coomassie-stained gel. B: histogram illustrating mean Ϯ SE changes in myofilament protein phosphorylation. N ϭ 8 hearts for each group. *P Ͻ 0.05 vs. control. maximum positive inotropy changes, which reach a sustained peak ϳ7.5 min after relaxin exposure (10) . We, therefore, conclude that relaxin does not modify cardiac myofilaments through the PKA signaling cascades in a time line consistent with the stimulatory effects of this hormone. Instead, we have found that PKC is acutely activated by relaxin to produce changes in myofilament function that are consistent with a positive inotropic effect.
Use of the PKC-␦-specific inhibitor rottlerin provided evidence to support the involvement of PKC-␦ in the intracellular signaling pathway activated by relaxin in ventricular myocardium. At the same time, we failed to observe any significant changes in the phosphorylation of T505 in PKC-␦, a change that has been proposed to occur with PKC-␦ activation (25) . The requirement for PKC-␦ T505 phosphorylation is the subject of some debate, as some studies have found that this modification is not necessary for PKC-␦ activation (28), while others disagree (14) . Our data suggest that PKC-␦ T505 phosphorylation is not a necessary step in mediating the intracellular effects of relaxin.
Several myofilament proteins are phosphorylated by PKC at multiple sites. In this study, we present the novel findings that relaxin increases myosin binding protein C, troponin I, and troponin T phosphorylation, and that PKC inhibition antagonizes most of the increased phosphorylation. Linking alterations in phosphorylation with the functional effects of relaxin is hampered by the complex nature of myofilament protein phosphorylation. For example, troponin I phosphorylation can increase or decrease myofilament Ca 2ϩ sensitivity, depending on the amino acids targeted by the kinase (18) . Similarly, troponin T contains four phosphorylatable residues, only one of which appears to mediate any functional effects (30) . We suggest that the troponin T phosphorylation that remains following PKC inhibition without any measurable changes in myofilament function is due to the fact that the phosphorylated sites are nonfunctional.
Myocardial stimulation may be mediated through increases in intracellular Ca 2ϩ transients, enhanced myofilament sensitivity to Ca 2ϩ , or some combination of both. Our results show that relaxin increases myofilament Ca 2ϩ sensitivity of force, which is consistent with its known cardio-stimulatory effects. Previous work by Piedras-Renteria and colleagues (21) found that relaxin increases calcium influx in atrial myocytes, although at higher doses of relaxin than that used here. Our data identify cardiac myofilaments as novel targets for relaxin in the heart, but they do not address whether relaxin alters intracellular Ca 2ϩ handling in ventricular myocytes. Further investigation of the effects of relaxin on ventricular myocyte Ca 2ϩ transients is needed to fully elucidate the intracellular mechanisms of relaxin.
Our data show that relaxin enhances myofilament Ca 2ϩ sensitivity of force without affecting actomyosin Mg-ATPase Ca 2ϩ sensitivity. This disconnect between force and ATP consumption is unusual, as it implies an increased forcegenerating capacity without a concomitant increase in energy use. Our laboratory has previously reported a similar disconnect in which pseudo-phosphorylation of troponin I decreased force production while increasing actomyosin Mg-ATPase activity (24) . For both cases, we suggest that the phosphorylation of troponin I may modify the nature of the actin-myosin cross bridges and affect myofilament efficiency. Normally, myosin will bind to actin and, with an ATP-dependent power stroke, generate a length step. If the cross bridge is not tightly bound, it may fracture part way through the power stroke, reducing the length step and decreasing force generation, while still consuming ATP. Conversely, if the cross bridge is more stable, the power stroke could continue for a greater distance, generating more force per ATP consumed. Our present study does not address the effects of relaxin on the physical states of the cross bridges, but is instead offered as a hypothetical model for future investigation.
Profound cardiovascular changes in the pregnant animal develop in conjunction with increases in circulating levels of relaxin (27) . Several studies have found that relaxin antagonism blocks many of the cardiovascular adaptations of pregnancy, including increased myocardial contractility (4) . While the vascular effects of relaxin have been attributed to increased angiogenesis, alterations in endothelin physiology, and vascular remodeling (1, 2), the mechanisms underlying increased stroke volume have not been investigated. Our data suggest that relaxin-dependent increases in cardiac myofilament Ca 2ϩ sensitivity could be invoked to explain the inotropic effects of relaxin in the hearts of pregnant animals. However, this proposal presupposes that relaxin works through the same intracellular mechanisms in the hearts of nonpregnant animals as it does in animals supporting a developing fetus. Given the changes in a variety of neurohumoral factors that mark preg- nancy, such an assumption is tenuous, and an investigation into relaxin's myocardial effects and mechanisms of action in the hearts of pregnant animals must be done to validate the extension of our data.
The emergence of relaxin as a pleiotropic hormone involved in a variety of physiological and pathological processes may offer some indication of the importance of this peptide. Its functional impact in health and disease has been the subject of a number of studies in recent years, but many of the intracellular mechanisms by which relaxin works remain unknown. The present study offers some insight into the myocardial effects of relaxin and the intracellular means by which it mediates these effects. To fully realize the clinical potential of this emerging hormone, further work must be done to fully identify the signaling pathways and intracellular targets of relaxin in the heart. Fig. 6 . PKC-␦ antagonism blocks relaxindependent regulation of cardiac myofilaments. Myocardium was treated with rottlerin to examine the role of PKC-␦ in relaxin-dependent regulation of cardiac myofilaments. A: pretreatment with rottlerin abolished the inhibitory effects of relaxin on actomyosin Mg-ATPase activity. Values are means Ϯ SE; N ϭ 7 hearts for all treatment groups. B: cardiac myofilaments were isolated posttreatment and separated by SDS-PAGE. Left: representative phosphorylation gel showing that relaxin-dependent increases in MyBP-C, TnT, and TnI phosphorylation were all blocked by the PKC-␦ inhibitor rottlerin. Right: protein loading is shown with a Coomassie-stained gel. *P Ͻ 0.05 vs. control. C: PKC-␦ may be phosphorylated at T505 in conjunction with activation. Immunoblot analysis using an anti-T505 phosphorylation antibody revealed no significant changed in PKC-␦ T505 phosphorylation following relaxin treatment of myocardium. Protein loading was assessed by probing immunoblots with an anti-actin antibody.
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